Listed by the USPTO as CORDAS, EMILY ANN
Tech Center 1600 • Art Units: 1632 1651 1683
This examiner grants 51% of resolved cases
CORDAS, EMILY ANN works in Tech Center 1600 and Art Unit 1632. The profile covers 554 resolved cases, with a 50.9% allowance rate and a 1293-day median to allowance. The interview lift is 57.4%, the strongest interview-associated figure in this profile, making examiner interviews a particularly important consideration in prosecution planning.
The listed companies are The Regents of the University of California, Merck Patent GmbH, and The University of North Carolina at Chapel Hill. The listed firms are Norton Rose Fulbright US LLP, OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and pH IP Law. Practitioners should align interview preparation with focused amendments and realistic timing expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17611500 | TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 | Final Rejection | Merck Patent GmbH |
| 18323667 | ENGINEERED NEOCARTILAGE TISSUE COMPOSITIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17919677 | CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17799851 | Regulating Activation of Fibroblasts to Prevent Fibrosis | Non-Final OA | The Regents of the University of California |
| 18600975 | METHOD FOR EVALUATING MIGRATION ABILITY OF MIGRATORY CELLS | Non-Final OA | TOPPAN HOLDINGS INC. |
| 18845273 | OPTIMIZED TRANSFECTION PROTOCOL | Non-Final OA | AMGEN INC. |
| 18552262 | NUCLEOTIDE EDITING TO REFRAME DMD TRANSCRIPTS BY BASE EDITING AND PRIME EDITING | Non-Final OA | The Board of Regents of The University of Texas System |
| 17407604 | Cardiac Muscle-Cell-Based Coupled Oscillator Network for Collective Computing and Related Methods | Non-Final OA | University of Virginia Patent Foundation |
| 18684668 | DIRECT REPROGRAMMING OF CELLS INTO CARDIAC PURKINJE-LIKE CELLS USING A UNIVERSAL SMALLMOLECULE COCKTAIL | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 18021596 | 3D NEURONAL TISSUE GRAFTS USING ULTRASHORT SELF-ASSEMBLING PEPTIDE SCAFOLDS | Non-Final OA | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 18293711 | DESIGNER MEMBRANELESS ORGANELLES SEQUESTER NATIVE FACTORS FOR CONTROL OF CELL BEHAVIOR | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18281154 | STEM CELL DIFFERENTIATION AND POLYMERS | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18024091 | METHODS FOR REPROGRAMMING TARGET CELLS | Final Rejection | Duke University |
| 18726671 | Cell Cultivation Methodology | Non-Final OA | Ronawk, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.9% of resolved applications examined by Emily Ann Cordas were allowed (554 resolved cases), compared with 38.1% across Art Unit 1632 over the last five years.
This examiner's interview lift is +57.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Emily Ann Cordas took 1,293 days on average from filing to allowance.
Emily Ann Cordas examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
